FDA bans unapproved gout treatments

FDA announced plans to ban unapproved gout treatments, favoring Mutual Pharmaceuticals' new version of the decades-old product, Colcrys. Hikma Pharma, which markets old-time colchicine, says its generics revenue growth will still come in at 20 percent. FDA release | Report

Suggested Articles

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.